A Model-Based Cost-Effectiveness Analysis of Abrocitinib Compared with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: A UK Healthcare Perspective

Background and objective: Janus kinase inhibitors (JAKi) are systemic therapies recommended by the National Institute for Health and Care Excellence (NICE) for moderate-to-severe atopic dermatitis (AD). However, no direct cost-effectiveness analyses of JAKi exist to guide decision-making. We evaluated the cost-effectiveness of abrocitinib versus upadacitinib and baricitinib in treating moderate-to-severe AD from a UK National Health Service (NHS) perspective.